Oncolytic virotherapy is an emerging treatment modality that uses replication-competent
viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a …

Early-stage clinical trials of oncolytic virotherapy have reported the safety of several virus
platforms, and viruses from three families have progressed to advanced efficacy trials. In …

Background Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes
oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the …

Most of the oncolytic herpes simplex viruses (HSVs) exhibit a high safety profile achieved
through attenuation. They carry defects in virulence proteins that antagonize host cell …

As a clinical setting in which novel treatment options are urgently needed, hepatocellular
carcinoma (HCC) exhibits intriguing opportunities for oncolytic virotherapy. Here we report …

Hepatocellular carcinoma (HCC) carries a dismal prognosis, with advanced disease being
resistant to both radiotherapy and conventional cytotoxic drugs, whilst anti-angiogenic drugs …

Cancer gene therapy expanded and reached its pinnacle in research in the last decade.
Both viral and non-viral vectors have entered clinical trials, and significant successes have …

A set of herpes simplex virus type 1 (HSV-1) amplicon vectors expressing the light chains
(LC) of botulinum neurotoxins (BoNT) A, B, C, D, E and F was constructed. Their properties …

Gene therapy has the potential to provide therapeutic benefits to hepatocellular carcinoma
(HCC) patients and has been the subject of intense pre-clinical and clinical research in …

Background Many studies have suggested that the immune response may play a crucial role
in the progression of hepatocellular carcinoma (HCC). Therefore, our aim was to establish a …